Hepatocellular carcinoma: Cost-effectiveness of screening. A systematic review

Risk Management and Healthcare Policy

Volumn 5, Issue , 2012, Pages 49-54

  Ruggeri, Matteo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Economic evaluations; HCC screening; Systematic review

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B VACCINE;

CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; ECHOGRAPHY; ECONOMIC EVALUATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PATIENT MONITORING; QUALITY ADJUSTED LIFE YEAR; RADIOFREQUENCY ABLATION; REVIEW; SYSTEMATIC REVIEW; VACCINATION;

EID: 84864420863     PISSN: None     EISSN: 11791594     Source Type: Journal    
DOI: 10.2147/rmhp.s18677     Document Type: Review

References (16)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750.
2. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94(8):2224-2229.
3. Sallie R. Screening for hepatocellular carcinoma in patients with chronic viral hepatitis: can the results justify the effort? Viral Hepatitis Rev. 1995;1:77-95.
4. Deuson RR, Brodovicz KG, Barker L, Zhou F, Euler GL. Economic analysis of a child vaccination project among Asian Americans in Philadelphia, Arch Pediatr Adolesc Med. 2001;155(8):909-914.
5. Yiu-Kuen BD, Ching LL, Man FY. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008;14(11):1652-1656.
6. Heyward WI, Lanier AP, McMaban BK. Screening for primary hepatocellular carcinoma among persons infected with Hepatitis B virus. JAMA. 1985;254(21):3052-3054.
7. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23(13):2892-2899.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236.
9. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98(7):1166-1175. Epub April 1, 2008.
10. Saab S, Ly D, Nieto J, Kanwal F, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl. 2003;9(7):672-681.
11. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98(3):679-690.
12. Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl. 2010;16(10):1186-1194.
13. Ladabaum U, Cheng SL, Yao FY, Roberts JP. Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation. Clinical Transplantation. 2011;25(2):283-291.
14. Bolondi L, Gaiani S, Casali A, Serra C, Piscaglia F. Screening for the early diagnosis of hepatocellular carcinoma: cost-effectiveness analysis. Radiol Med. 1997;94(1-2):4-7.
15. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut. 2001;48(2):251-259.
16. ISPOR, Country specific pharmacoeconomic guidelines, ISPOR 2006. Available from: http://www.ispor.org/PEguidelines/index.asp. Accessed January 24, 2012.